Business Wire

UK National Institute for Health and Care Excellence (NICE) Updates Endobronchial Valve Treatment Guidance to Standard Care

Jaa

Pulmonx® Corp. today announced that the UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance for endobronchial valves used to treat severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD), and now considers current evidence sufficient to support routine use.

The change in NICE guidance is based on safety and efficacy data from multiple randomized clinical trials evaluating Zephyr® Endobronchial Valves (EBV®), which have demonstrated benefits for patients in quality of life, exercise capacity and lung function, as well as long-term safety. In fact, four randomized controlled trials of the Zephyr EBV (BeLieVeR-HiFI, TRANSFORM, STELVIO and IMPACT) provide a significant body of evidence supporting the ability of the treatment to significantly improve lung function, exercise tolerance and quality of life in emphysema patients with no collateral ventilation, as assessed with the Chartis System.1,2,3,4

“In light of the high burden of symptoms, progressive nature of emphysema and poor prognosis for patients, the NICE decision means that patients with severe emphysema should be referred to specialists to determine if they are good candidates for endobronchial valves or other interventions,” said Pallav Shah, MD, consultant physician in respiratory medicine at Royal Brompton Hospital and Chelsea & Westminster Hospital, London.

The British Lung Foundation estimates that in the UK, 1.2 million people are living with diagnosed COPD and almost 30,000 die from the disease every year.5 Roughly one-third of COPD patients have a form of the disease called emphysema.6 Emphysema causes damage to the alveoli, the air sacs in the lungs, which allows air to escape and prevents patients from taking in full breaths. This chronic breathlessness makes even the simplest daily activities difficult, such as washing, eating, walking and household chores, and often leads to patients becoming housebound and depressed. In fact, the quality of life for emphysema patients is worse than that for lung cancer.7

Zephyr EBVs are tiny, minimally-invasive, one-way valves placed via a flexible bronchoscope in airways in the lungs to occlude diseased regions and reduce lung hyperinflation. As a result, the remaining healthier regions can function more efficiently, enabling better breathing and an improved quality of life for patients.

Zephyr EBVs are routinely used in Europe and Australia as a treatment for severe emphysema. The treatment has been included in influential international guidelines from such groups as the Global Initiative for Chronic Obstructive Lung Disease (GOLD).8 The well-known independent Cochrane Airways Group also published a review of the available evidence earlier this year and concluded that, with proper patient selection, bronchoscopic lung volume reduction techniques – such as the Zephyr EBV – should be considered for severe emphysema patients when medical therapy has failed.9

Germany and Switzerland have supported EBV use in eligible patients for several years, and late last month, the Dutch organization for reimbursement – the Zorginstituut Nederland – ruled that EBVs are considered an effective treatment in adult patients with severe emphysema and will now be covered by the government.10

“These decisions will increase patient access to our proven and minimally-invasive Zephyr technology, which has the potential to significantly improve the quality of life for patients,” said Pulmonx CEO Glen French.

Over the past 10 years, more than 50,000 Zephyr EBVs have been implanted globally in more than 12,000 patients. To view a video of the Zephyr EBV procedure, click here.

About Pulmonx

Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com.

The Zephyr EBVSystem is an investigational device in the United States. Limited by U.S. law to investigational use only.

1. Klooster K, Ten Hacken NHT, Hartman JE, Kerstjens HAM, Van Rikxoort EM, Slebos DJ. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med 2015; 373:2325-2335.
2. Davey C, Zoumot Z, Jordan S, McNulty W, Carr D, Hind M, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet 2015;386(9998):1066-73.
3. Kemp SV, et al. A multicenter RCT of Zephyr Endobronchial Valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med 2017;https://doi.org/10.1164/rccm.201707-1327OC
4. Valipour A, et al. Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT study. Am J Respir Crit Care Med 2016;194(9):1073-1082.
5. https://statistics.blf.org.uk/copd
6. http://www.lung.org/assets/documents/research/copd-trend-report.pdf
7. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000;55(12):1000-1006.
8. http://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf
9. http://www.cochrane.org/CD012158/AIRWAYS_bronchoscopic-lung-volume-reduction-procedures-moderate-severe-chronic-obstructive-pulmonary-disease
10. https://www.zorginstituutnederland.nl/publicaties/standpunten/2017/09/14/standpunt-endobronchiale-longvolumereductie-middels-eenrichtingskleppen-bij-ernstig-longemfyseem

Contact information

Chronic Communications
Michelle McAdam
(949) 545-6654 or (310) 902-1274
michelle@chronic-comm.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

GSMA Announces Nominees for 2018 GLOMO Awards24.1.2018 12:00Tiedote

The GSMA today announced the nominees for the Global Mobile Awards 2018 (GLOMO Awards). Winners of the awards will be presented throughout Mobile World Congress, which takes place 26 February – 1 March in Barcelona. The full list of nominees can be found at http://gsma.at/glomoshortlist. "The GLOMOs offer organisations and individuals from across the world an opportunity to showcase how mobile technology continues to inspire new levels of ingenuity, innovation and achievement,” said Michael O’Hara, Chief Marketing Officer, GSMA. “As always, the calibre of entries is extremely high, so to be shortlisted for the GLOMOs today is quite an achievement in itself. We wish the very best of luck to all nominees and look forward to unveiling the winners at Mobile World Congress next month.” The GLOMO Awards feature an afternoon ceremony at 15:30 CET on Tuesday, 27 February in Auditorium 5, Hall 4, and will include the presentation of winners in three categories including “Social Good”, “Governme

GleSYS Tap Into Telia Carrier Backbone to Increase Capacity and Support Growth Plans24.1.2018 12:00Tiedote

Telia Carrier announced today that it is working with one of Sweden’s fastest growing hosting companies, GleSYS , to provide improved capacity and support future growth plans. GleSYS will be connecting to the Telia Carrier global backbone, one of the largest in the world, and the first to be 100G enabled in Europe and North America. GleSYS provides hosting and data centre services to over 4,000 customers in 70 countries. With two fully redundant datacentres in Sweden and a network of cloud hosting locations, GleSYS supports a range of industries, such as eCommerce, where performance, responsiveness and reliability on a global scale have a direct impact on revenues and are therefore critical. Telia Carrier will be providing 100G IP Transport and wavelength network transport services to double available capacity on GleSYS’ current infrastructure, which provides cloud hosting, dedicated servers and colocation in multiple sites across Europe. Eric Lindsjö, Head of Networks at GleSYS, said;

Düsseldorf Airport to Deploy Next Generation ECAC Standard 3 EDS Screening Technology from Smiths Detection24.1.2018 12:00Tiedote

Smiths Detection is supplying next generation hold baggage scanners to support the upgrade to ECAC Standard 3 explosives detection systems (EDS) at Düsseldorf Airport. Awarded by the Procurement Office of the German Ministry of Interior, the contract includes 14 advanced HI-SCAN 10080 XCT scanners, which deliver exceptional levels of security; and can be further updated as necessary in the future to detect new explosive threats. There is also an associated eight year service agreement. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180124005070/en/ Düsseldorf Airport to deploy next generation ECAC Standard 3 EDS screening technology from Smiths Detection (Photo: Business Wire) “European airports are currently very focused on upgrading to ECAC Standard 3 approved EDS to meet the new regulations,” commented Tony Tielen VP EMEA, Smiths Detection. “This does, of course, require a financial investment which must be clearly weighed

Integral Expands Cryptocurrency Market Data Services to Include 14 Cryptocurrencies and 16 Exchanges24.1.2018 01:00Tiedote

Integral (www.integral.com), the financial technology partner trusted by leading banks, brokers, and investment managers to design, deliver and grow their FX businesses, announced today that it has expanded its market data offering for cryptocurrencies to include 14 major cryptocurrencies connecting to all major exchange sources across the U.S., Europe and Asia including Japan and Hong Kong. “An accurate, stable, and reliable reference price is a requirement for any market maker,” said Harpal Sandhu, CEO of Integral. “The Cryptocurrency Market Data Service connects to the most price sources and applies the most advanced price discovery algorithm available.” Integral has years of experience as a technology leader and innovator in foreign exchange and is now applying this ingenuity to the cryptocurrency market. The Market Data Service uses algorithms developed with Stanford University for Integral FX Benchmark to provide the most precise reference prices for cryptocurrencies. “Integral’s

Kimbal Riley to Become Vista Group CEO24.1.2018 00:57Tiedote

Vista Group International (NZX & ASX: VGL) has today announced that Kimbal Riley will take over as Group CEO from Murray Holdaway. Mr Holdaway will take up the position of Chief Product Officer (CPO) for Vista Group, and will continue in his role as an Executive Director on the Vista Group board. This has taken place as part of a succession planning process and will deliver a seamless transition within the business. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180123006545/en/ Kimbal Riley becomes CEO of Vista Group International (Photo: Business Wire) Mr Riley has had an extensive career in senior executive roles in the IT and Services industries in New Zealand and overseas. He joined Vista Group four years ago, with the past two years as CEO of Vista Entertainment Solutions (VES), which is responsible for the largest proportion of the Group’s revenue. He has been focused on building scale in the business and under his lea

IFF Breaks Ground on Flavors/Fragrances Site in Sri City, India23.1.2018 20:00Tiedote

Regulatory News: International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, has broken ground on a new flavors and fragrances plant located in Sri City, in the State of Andhra Pradesh in India. Part of a larger investment into the Greater Asia region, the plant is expected to be commercialized in December 2019. The new facility, which will be the largest flavor and fragrance manufacturing facility in India and the largest IFF site in Greater Asia, occupies a 32-acre/130,000m2 plot and will serve IFF flavors and fragrances customers across India and the region. “In this economically vibrant country, it is critical that we invest to provide our customers with winning tastes and scents,” said IFF Chairman and CEO Andreas Fibig. “This new facility is fitted with capabilities tailored for our customers’ needs. Coupled with our excellent consumer insights teams and their deep understanding of the local markets, w

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme